Ann Woolfrey

Appointments and Affiliations

 
 
Fred Hutchinson Cancer Research Center
Clinical Research
Associate Member
University of Washington
School of Medicine
Pediatrics
Professor
Professional Headshot of Ann Woolfrey

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N.
P.O. Box 19024
D5-390
Seattle, Washington 98109-1024
United States

Contact

Phone: (206) 667-4453
Fax: (206) 667-4937
awoolfre@fhcrc.org

Degrees

M.D., University of Minnesota, Medicine, 1984.
B.A., Saint Olaf College, 1979.

Research Interests

Hematopoietic cell transplant (HCT) is the only curative therapy for many life-threatening hematologic diseases, and theoretically could cure other chronic hematologic and immunologic disorders. The research projects under Dr. Woolfrey’s direction are aimed toward improving the effectiveness of hematopoietic cell transplants, particularly for patients with nonmalignant disorders. These studies explore the use of lower dose (nonmyeloablative) conditioning regimens to reduce the short and long term toxicities associated with HCT, the use of HCT to restore normal immunity in patients with HIV or refractory autoimmune diseases, and the use of alternative donors, including unrelated and mismatched related donors.

Clinical Studies
1. Nonmyeloablative conditioning regimen using low-dose total body irradiation with or without fludarabine for treatment of immune deficiencies, metabolic storage diseases, hemaglobinopathies, and other inherited disorders. The primary goal of each study is to determine whether establishment of stable mixed chimerism using a low-toxicity regimen results in amelioration of the disease, as an alternative to standard transplant procedures.

2. Nonmyeloablative conditioning regimen using low-dose total body irradiation and fludarabine for treatment of HIV. The primary goal is to determine whether immunity can be reconstituted in HIV patients using a non-toxic regimen for HCT. A second goal is to establish a method for allogeneic transplant that is tolerated by patients with HIV for cure of life-threatening malignancies.

3. High-dose immunoablative therapy followed by autologous HCT for treatment of refractory autoimmune disorders. The primary goal is to determine whether immune ablation followed by rescue with purified autologous stem cells could result in restoration of immunity without recurrence of the autoreactive T cells. Patients eligible include children with juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, or dermatomyositis.

4. Use of haploidentical donors for HCT in the treatment of life-threatening hematologic diseases in children. The goal of these studies has been to determine the outcome of transplants for patients who undergo HCT using haploidentical donors.

Additional Experience

Hematology
Oncology
Pediatrics
Medicine
Bone Marrrow Transplantation
Hematopoietic Cell Transplantation
Immunology

Future Research

Immune Reconstitution
Tolerance
HIV
Juvenile Rheumatoid Arthritis

Languages

(Reading, Writing, Speaking)

English: (Fluent, Fluent, Fluent)

Memberships

American Society for Blood and Marrow Transplantation
American Society of Hematology
Society for Leukocyte Biology
Society for Pediatric Research

Honors and Awards

1994, American Cancer Society Young Investigator Honored Presentation, American Cancer Society
1984, Minnesota Medical Foundation Undergraduate Research Award,
1978, Honors Program, Cambridge University, Cambridge, England

Previous Positions

2003, Associate Professor, University of Washington, School of Medicine, Pediatrics
2002, Associate Member, Fred Hutchinson Cancer Research Center, Pediatric Bone Marrow Transplantation and Immunogenetics, Clinical Research Division
2000-2003, Assistant Professor, University of Washington, School of Medicine, Pediatrics
1996-2002, Assistant Member, Fred Hutchinson Cancer Research Center, Pediatric Bone Marrow Transplantation and Immunogenetics
1996-2002, Acting Assistant Professor, University of Washington, School of Medicine, Pediatrics
1995-1995, Director, Yale University, School of Medicine, Pediatrics, Pediatric Stem Cell Program
1995-1995, Instructor, Yale University, School of Medicine, Pediatrics
1994-1994, Associate in Clinical Research, Fred Hutchinson Cancer Research Center, Clinical Transplantation Support, Clinical Research Division
1992-1995, Senior Research Fellow, Fred Hutchinson Cancer Research Center and Virginia Mason Research Center

 

Recent Publications

Submitted
Ballen, KK, Woolfrey AE, Zhu X, Woo Ahn K, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL et al..  Submitted.  Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
2014
2013
2012
2011
2010
Woolfrey, AE, Lee SJ, Gooley TA, Malkki M, Martin PJ, Pagel JM, Hansen JA, Petersdorf EW.  2010.  HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(10):1382-7. Abstract
Guinan, E, Luzmik L, Handgretinger R, Woolfrey AE.  2010.  Preservation of immune repertoire by selective depletion of haploidentical grafts.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(1 Suppl):S68-74. Abstract